23:57 , Aug 12, 2013 |  BC Extra  |  Financial News

Bind proposes IPO

Bind Therapeutics Inc. (Cambridge, Mass.) proposed to raise up to $80.5 million in an IPO underwritten by Credit Suisse; Cowen; Stifel; and JMP Securities. Bind is developing Accurins, which are selective and programmable nanoparticle-encapsulated therapeutics...
07:00 , Apr 8, 2013 |  BC Week In Review  |  Company News

Bind Therapeutics, Pfizer deal

Bind (formerly Bind Biosciences Inc. ) and Pfizer partnered to develop and commercialize Accurins using undisclosed small molecules provided by the pharma for undisclosed diseases. Accurins are selective and programmable nanoparticle-encapsulated therapeutics that are designed...
23:32 , Apr 3, 2013 |  BC Extra  |  Company News

Bind, Pfizer in Accurins deal

Bind Therapeutics Inc. (Cambridge, Mass.) and Pfizer Inc. (NYSE:PFE) partnered to develop and commercialize Accurins using undisclosed small molecules provided by the pharma for undisclosed diseases. Accurins are selective and programmable nanoparticle-encapsulated therapeutics that are...
08:00 , Mar 4, 2013 |  BC Week In Review  |  Financial News

Bind Biosciences completes venture financing

Bind Biosciences Inc. , Cambridge, Mass.   Business: Cancer, Drug delivery   Date completed: 2/8/13   Type: Venture financing   Raised: $8.7 million   Investors: Existing investors   Note: The company raised $8.7 million of...
08:00 , Jan 21, 2013 |  BioCentury  |  Product Development

Bonding with Amgen

Amgen Inc. is betting that Bind Biosciences Inc. 's Accurin nanotechnology can overcome one of the major limitations for kinase inhibitors in cancer: the fact that these drugs affect healthy and cancerous cells equally. The...
08:00 , Jan 14, 2013 |  BC Week In Review  |  Company News

Amgen, Bind Biosciences deal

Bind and Amgen partnered to develop and commercialize an Accurin therapeutic for solid tumor indications selected by Amgen. Accurins are selective and programmable nanoparticle-encapsulated therapeutics, which are designed to accumulate at the site of disease....
08:00 , Jan 14, 2013 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones Biocon Ltd. (NSE:BIOCON; BSE:BIOCON) was off Rs9.10 to Rs282.45 last week on India's National Stock Exchange after the Drugs Controller General of India approved Alzumab itolizumab to treat chronic plaque psoriasis. The company...
01:24 , Jan 9, 2013 |  BC Extra  |  Top Story

Bind, Amgen in Accurin deal

Bind Biosciences Inc. (Cambridge, Mass.) and Amgen Inc. (NASDAQ:AMGN) partnered to develop and commercialize an Accurin therapeutic for solid tumor indications to be selected by Amgen. Accurins are selective and programmable nanoparticle-encapsulated therapeutics that are...
08:00 , Dec 24, 2012 |  BioCentury  |  Finance

Blend goes platinum

Blend goes platinum Blend Therapeutics Inc. will use last week's $16 million series B round to take one cancer program to an IND and a second to IND-enabling studies. The lead programs include a "monofunctional"...
07:00 , Sep 27, 2012 |  BC Innovations  |  Tools & Techniques

Slipping therapeutics to the mitochondria

Researchers from The University of Georgia have developed a polymeric nanoparticle technology that can selectively deliver small molecules to the mitochondria of cultured cells. 1 The researchers now are evaluating the nanoparticles in animal models...